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Abstract 
Response inhibition has been frequently studied in OCD with mixed results. The inconsistent 
findings may stem, in part, from a failure to consider the heterogeneity of disorder. This study 
examines behavioural and ERP components (N2 and P3) during a simple response inhibition 
Go/NoGo task in a sample of 48 OCD and 53 control participants. Comparisons in behavioural 
and electrophysiological measures were made between groups (OCD vs control), and within 
the OCD group itself in terms of symptoms clusters (symmetry, forbidden thoughts and 
cleaning) and co-morbidity status (OCD only, OCD with depression). In the OCD group the 
N2 component appeared more frontally localised compared to the control group. Participants 
with OCD demonstrated longer N2 latency and a larger difference in N2 between the NoGo 
and Go conditions, suggesting slower but more greater conflict monitoring. P3 had a larger 
amplitude in the OCD group compared to controls, indicative of greater response inhibition but 
it was also was reduced in the NoGo compared to the Go condition, suggesting suppressed 
response inhibition. No significant differences were found between symptom clusters, but 
those with OCD made more omission errors than those with OCD and comorbid depression. 
The latter also had faster P3 latencies, which combined with the behavioural data indicates 
slightly improved response inhibition when comorbid depression is found. Based on the results 
presented, it would seem unlikely that symptom clusters has contributed to previous 
inconsistencies, but comorbid depression could have impacted and should be considered in 
future research.  
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Background  
Obsessive Compulsive Disorder (OCD), characterised by recurrent obsessions and 
compulsions, affects 1-3% of the general population (1-3). Although classified as a single 
condition, individuals with OCD have varied experiences (4). One way to characterise OCD in 
an individual is to use the Yale Brown Obsessive Compulsive Scale (Y-BOCS), which is 
considered the gold standard tool for assessing severity and symptom diversity in OCD (5, 6). 
Several studies have used the Y-BOCS to identify symptom clusters, including a large meta-
analyses examining factor analytic studies which found that four factors explain 79% of the 
variance in OCD symptoms: i) Symmetry ii) Forbidden thoughts iii) Cleaning iv) Hoarding (7-
9). These four clusters appear stable across the lifespan and robust to differences in factor 
analytic techniques of individual meta-analyses. The same four clusters have been confirmed 
in other studies (10, 11), although under DSM-5, hoarding became a separate classification, 
leaving three symptom clusters within OCD (12). As well as symptom heterogeneity, which 
may be identified with the Y-BOCS, individuals with OCD often have psychiatric 
comorbidities, most notably depression (13). Critically, symptom cluster and comorbidity are 
known to impact on treatment responsiveness and therefore it is beneficial to better understand 
this heterogeneity (8, 14-16). Despite the importance of these factors, to date, research has 
typically not accounted for the heterogeneity of OCD symptoms and comorbidities within 
study designs which may have contributed to mixed findings in some areas (17). One such area 
of research is response inhibition. 
 
Several studies have identified differences in performance on  response inhibition tasks in 
OCD, when compared with healthy control participants, using Go/NoGo tasks (18, 19), but 
findings are inconsistent. Behavioural measures show both faster reaction times (20) and 
slower reaction times in OCD (21). There are also reports of altered error rates (22), whilst 
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others find no differences in any measure (23-29) in OCD. Of these studies, only one (26) noted 
the symptom cluster and did not consider this as a variable in the analysis. In the majority of 
the studies, those with comorbidities including depression were excluded (20-24, 28, 29), and 
where comorbid depression was recorded (25-27), it was not differentiated in the analysis. The 
failure of these studies to take into account two important sources of heterogeneity in OCD 
may have in part contributed to the inconsistent findings. 
 
Neurophysiological data from Go/No-Go tasks focuses on the Event Related Potentials (ERPs) 
N200 (negative deflection at frontal and central sites at 200 – 300 ms) and P300 (positive 
deflection at frontal and central sites at 300 – 600 ms, (30)), often considered collectively as 
the N2/P3-complex (31). These N2 and P3 components are associated with the early and late 
phases of response inhibition, respectively, and would normally be increased in inhibition 
conditions (30). Analysis of N2/P3 complex in OCD show inconsistent results; N2 has been 
reported to be both increased (22, 32, 33) and decreased (26, 27, 34) in OCD and P3 has also 
been reported as both increasing and decreasing in different studies of OCD (32, 33, 35, 36) or 
not changing at all. As with the behavioural data, only one study noted symptom cluster but 
did not analyse according to it (26). The majority also excluded those with comorbid depression 
(22, 32, 33, 35, 36) with the remaining three studies including those with depression but not 
accounting for this in their analysis ((26, 27, 34). This again demonstrates that key sources of 
heterogeneity have been neglected in previous studies. 
 
Whilst inconsistent results may be attributed to differences in the exact task and medication 
status, for example, we propose that failure to consider the heterogeneity of the disorder, 
specifically in terms of symptom clusters and comorbid depression, may also have contributed 
to the mixed findings. The aim of this study was, therefore, to assess response inhibition using 
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the Go/No-Go task, which has previously found inconsistent results, in a manner that allows 
consideration of symptom cluster and comorbid depression, in addition to considering the 
disorder as a whole to allow comparison with previous studies. Because of the inconsistencies 
reported in previous work and the fact that no studies to date have been conducted using the 
symptom clusters as defined by Bloch et al. (9) and DSM-5 (12), we have employed two-tailed 
hypotheses. Specifically, we hypothesised that there would be significant differences in 
response inhibition between i) control and OCD participants and ii) OCD participants with 
different symptom clusters and comorbidity status. 
Methods  
Participants 
Ethical approval was obtained from the institutional ethics committee (Ref 
HREC/2012/#1191/1) and the work was conducted in accordance the Declaration of Helsinki. 
All participants provided written consent to participate. 
 
Participants (OCD = 48; Control = 53) aged 18-60 years were recruited through local 
advertising. All participants had completed secondary education and reported no history of 
brain injury or neurological disorder. Control participants were included only if they could 
confirm no current or previous psychiatric disorders. Additionally, ten randomly selected 
control participants completed the Y-BOCS to confirm subclinical scores on the YBOCS as 
indicated in the standard YBOCS illness classification (i.e. less than 7 out of 40) (37), as 
expected for a healthy population.  OCD participants were included only if they had an existing 
diagnosis of OCD which was validated using the Y-BOCS during participant screening, 
resulting in a score within the clinical range i.e. over 7 out of a possible 40. The average total 
YBOCS score, a marker of illness severity, for all OCD participants was 20.88 ± 1.78, which 
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is classed as moderate OCD. In all cases YBOCS assessment was carried out by a researcher 
qualified and deemed competent in administering psychological assessment. A current 
diagnosis of comorbid major depressive disorder was reported in 58% of those with OCD 
participating in the study. Participants experiencing other comorbid conditions were excluded 
from the study. Control and OCD groups were matched for gender, age, years in education and 
handedness (Table 1). 
Characterisations of OCD groups 
As indicated above, all OCD participants completed the Y-BOCS to confirm diagnosis at the 
time of testing. The total Y-BOCS score also provided a measure of illness severity. Each OCD 
participant was allocated to one of the three clusters based on their responses to the Y-BOCS 
Symptom Checklist, which contains over 50 commonly reported obsessions and compulsions 
across several categories, allowing participants to self-identify their most prominent symptoms. 
The clusters were matched for gender, age, years in education, handedness, age of onset, illness 
duration, illness severity, medication and use of cognitive behavioural therapy (CBT) (Table 
2). There were no differences between the OCD only and OCD with comorbid depression 
group in terms of gender, age, years in education, handedness, age of onset, illness duration, 
illness severity, medication and use of CBT (Table 3).  
Procedure – Behavioural Paradigm 
Participants completed the commonly used Visual Continuous Performance Task (VCPT; 
PsyTask Software for the Mitsar System (38, 39)) with Go and NoGo conditions. We opted to 
use a Go/No-Go measure of response inhibition because this is an area where inconsistencies 
have previously been found as discussed above and the task is also very simple for participants. 
During each trial two stimuli were presented in stimulus pairs, as is standard practice for this 
task. Using this paired approach allows some separation of two operations in time: preparation 
to receive a stimulus and preparation to make a movement (40). It is hypothesized that the ERP 
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in response to the first stimulus in a pair represents sensory disengagement while the ERP in 
response to the second stimulus, which determines whether the trial is a Go or No-Go trial, 
represents motor suppression i.e. a component of response inhibition. At the start of each trial 
a black fixation cross appeared at the centre of the screen. After 300ms, the first stimulus was 
presented for a period of 100 ms. This stimulus then disappeared and was replaced by the 
fixation cross for a further 1000 ms, before the second stimulus appeared for a period of 100 
ms. There was then a 1500 ms response period. Stimulus timing and images for the two 
conditions are shown in Figure 1. The different stimuli were matched for size, luminance and 
colour. For the Go condition participants instructed to press the left mouse button as fast as 
possible when the second stimulus is an animal, and for the NoGo condition, participants 
instructed to suppress their response and not click the mouse button when the second stimulus 
is a plant. Trials were presented in a pseudorandomised manner to ensure 100 trials of each 
condition were presented. Three behavioural measurements were made: reaction time for 
correct responses; the number of omission errors (not pressing in a Go trial) and iii) commission 
errors (pressing in NoGo trial). Before the experiment participants had the opportunity to 
practice the task. 
EEG Recording - Event Related Potential 
EEG was continuously recorded using the WinEEG (Version 2.93.59) Mitsar 21 channel EEG 
system (38) with nineteen pure tin scalp electrodes on a preformed electrode cap (41) 
positioned according to the international 10-20 system (42). The reference electrodes (A1, A2) 
were positioned on each earlobe. A ground electrode was placed on the midline three 
centimetres anterior to Fz (frontal midline electrode). Impedance levels were kept under 5 kΩ. 
EEG was digitally recorded on a common average montage (43). Band pass Butterworth filters 
were set at low pass filter 0.53 Hz, high pass filter 50 Hz, and a notch filter 45-55 Hz. The data 
input signals were digitised at a sampling rate of 250 Hz. Independent Component Analysis 
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was used to identify and remove components representing horizontal and vertical eye 
movements. Periods involving pulse-like voltages exceeding 75μV or slow frequencies 
between 0 and 1 Hz exceeding 75μV were discarded by automated rejection. 
Electromyography (EMG) was manually removed. Raw EEG data was baseline corrected using 
a pre-stimulus period of 300 ms and quantified by peak amplitude and peak latency of the N2 
and P3.  
Data Analysis 
All data analysis was conducted in SPSS and used parametric testing after first confirming the 
data was suitable using the Kolmogorov-Smirnov Test and measures of skewness and kurtosis. 
For ANOVAs where the sphericity assumption was violated data is reported for the 
Greenhouse-Geiser correction (44).  Hypothesis 1 (Control vs. OCD): For the behavioural data, 
reaction time, commission and omission errors were compared using an independent sample t-
test. For the ERP data, N2 and P3 were maximal at frontal central electrodes, in line with 
previous studies (30, 31) and, therefore, data from Fz, Cz and Pz only were selected for 
analysis. For both components, peak amplitude and peak latency were analysed. In addition, 
the amplitude of a difference wave was calculated by subtracting the Go response from the 
NoGo response to give an N2d (difference) and a P3d (difference). It is suggested that N2d 
represents conflict monitoring whilst P3d represents response inhibition (41). Analysis of N2 
and P3 amplitude was conducted using a Mixed ANOVA with GROUP (control, OCD) as the 
between-measures factor and CONDITION (Go, NoGo) and SITE (Fz, Cz, Pz) as within 
measures factors. P3 latency was also analysed using this method. However, N2 latency was 
analysed using only GROUP and CONDITION because the amplitude analysis revealed that 
N2 was only present in both groups at Fz, meaning SITE was not relevant. N2d was analysed 
using an independent sample t-test for this same reason whilst P3d was analysed using a Mixed 
ANOVA with GROUP as the between-measures factor and SITE as the within-measures factor.  
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Hypothesis 2 (within OCD): Rather than conduct one large analysis that included both 
comorbidity status and symptom cluster we opted to analyse the two separately due to the small 
samples that would have arisen if combined (e.g. comorbid depression and symmetry cluster 
N=3). To investigate the effect of cluster on response inhibition the behavioural data were 
compared using One-Way ANOVA. For ERP responses P3 amplitude and latency were 
analysed with a Mixed ANOVA with CLUSTER as the between-measures factor and 
CONDITION and SITE as within measures factors. For N2 amplitude and latency, which is 
only found at Fz in participants with OCD, a Mixed ANOVA with CLUSTER as the between-
measures factor and CONDITION only as a within measure factor was used. P3d was analysed 
using a Mixed ANOVA with CLUSTER as the between-measures factor and SITE as the 
within-measures factor whilst N2d was compared using One-Way ANOVA. Comorbidity 
analysis was conducted in the same way but cluster was replaced with COMORBIDITY as the 
between-measures factor for all ANOVAs and One-Way ANOVAs were replaced with 
independent-sample t-tests.  
 
Results 
ERP but not behavioural measures differentiate between OCD and control participants 
There was no significant difference in the mean reaction time for correct responses between 
control (Mean ± SD; 339.5 ± 63.0 ms) and OCD participants (354.6 ± 78.4 ms; t (99) = 1.069, 
p = 0.288; Figure 2A). There were also no differences in the number of omission errors (Control 
= 2.3 ± 3.0; OCD = 1.9 ± 2.2; t (99) = 0.655, p = 0.514, Figure 2B) or commission errors 
(Control = 0.9 ± 0.0; OCD = 0.8 ± 0.2; t (99) = 0.415, p = 0.679, Figure 2C) between the two 
groups.  
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Grand averages of the ERP responses of the OCD and control groups are shown in Figure 3. 
Analysis of N2 amplitude revealed a significant main effect of GROUP (F (1, 99) = 5.64, p = 
0.019) with the control group having a larger overall N2 component when all sites are 
considered. There was also a significant main effect of CONDITION (F (1, 99) = 80.12, p < 
0.001), with the NoGo condition eliciting a greater N2 response. Finally, there was a significant 
main effect of SITE (F (2, 198) = 134.91, p < 0.001); pairwise comparisons show all sites 
differed significantly from each other (p < 0.001 Fz>Cz>Pz). There was no negative response 
at Pz indicating N2 was not found at this location when both groups are considered together. 
There was a significant SITE x GROUP interaction (F (2, 198) = 13.22, p < 0.001) with 
interaction contrasts revealing that N2 was no different between the two groups at Fz, both 
groups lacked a response at Pz and finally, the Cz response was significantly different due to 
no appreciable negative response being present in the OCD group. There was no significant 
GROUP x CONDITION interaction (F (1, 99) = 0.13, p = 0.910). There was a significant SITE 
x CONDITION interaction (F (2,198) = 26.62, p < 0.001) driven by the difference in Go and 
NoGo and the fact that N2 is not present at all sites. There was a significant GROUP x SITE x 
CONDITION interaction (F (2, 198) = 21.88, p < 0.001). Examination of the contrasts revealed 
this interaction arises because of the more localised N2 in OCD participants and the fact that 
N2 is greater at the frontal location in the NoGo condition in comparison to the Go Condition.  
 
N2 latency analysis focussed on Fz because this was the only location in which it was present 
for both groups revealed a significant main effect of GROUP (F (1, 99) = 6.81, p = 0.01) with 
the OCD group having a significantly larger latency, i.e. a slower response. There was also 
significant main effect for CONDITION (F (1, 99) = 10.79, p = 0.001) with larger latencies, 
i.e. slower responses in the Go condition. There was no significant interaction (F (1, 99) = 1.06, 
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p = 0.306). Finally, N2d analysis revealed that the OCD group had a larger difference between 
the two conditions than the control group (t (99) = 2.37, p = 0.020). 
 
Analysis of P3 amplitude found a significant main effect of GROUP (F (1, 99) = 8.43, p = 
0.005) with the OCD group having a larger P3 amplitude. There was also a significant main 
effect of CONDITION (F (1, 99) = 113.42, p < 0.001), with the NoGo condition eliciting a 
greater amplitude. Finally, there was a significant main effect of SITE (F (2, 198) = 164.29, p 
< 0.001) with pairwise comparisons showing all sites differed significantly from each other (p 
< 0.001 Cz>Pz>Fz). There was a significant SITE x GROUP interaction (F (2, 198) = 12.56, 
p<0.001). To break this down, interaction contrasts were performed comparing P3 amplitude 
across the electrode sites and revealed that controls have a larger P3 at Fz, whilst those with 
OCD have higher P3 amplitudes at Cz and Pz. There was also a SITE x CONDITION 
interaction (F (2,98) = 149.16, p < 0.001). This was driven by the fact that in the Go condition 
the responses at Cz and Pz were comparable and larger than at Fz, whilst in the NoGo condition, 
responses were greatest at Cz and comparable and lower at Fz and Pz. Finally, there was a 
significant GROUP x CONDITION interaction (F (1, 99) = 5.99, p = 0.016). Again, 
examination of the data and interaction contrasts revealed that this interaction was due to a 
greater P3 amplitude difference between the OCD and controls in the Go Condition compared 
to the NoGo condition (p = 0.016). There was no significant GROUP x SITE x CONDITION 
interaction (F (2, 198) = 0.45, p = 0.64) 
 
P3 latency analysis showed no significant main effect of GROUP (F (1, 99) = 0.00, p = 0.996), 
but there was a main effect of CONDITION (F (1, 99) = 7.57, p = 0.007), with larger P3 
latencies i.e. slower responses in the Go condition. There was also a main effect of SITE (F 
(1.54, 151.92) = 78.39, p < 0.001). Contrasts revealed that the P3 response was slowest at Fz 
12 
 
(p < 0.001) and fastest at Pz (p < 0.001). There was no significant GROUP x SITE interaction 
(F (1.54, 151.92) = 1.25, p = 0.283) or GROUP x CONDITION interaction (F (1, 99) = 2.28, 
p = 0.135). However, there was a significant SITE x CONDITION (F (2,198) = 3.23, p = 0.042) 
with latencies in the Go condition varying more with SITE than in the NoGo condition. There 
was a significant GROUP x SITE x CONDITION (F (1.76, 173.89) = 3.23, p = 0.048). 
Examination of the interaction contrasts revealed that the difference in P3 latency between the 
Go and NoGo conditions across the OCD and control group differed between Fz and Pz (p = 
0.025) and Cz and Pz (p = 0.041).  P3d amplitude analysis revealed a significant main effect 
of GROUP (F (1,99) = 5.99, p = 0.016) with larger responses in the control group. In addition, 
there was a main effect of SITE (F (2,198) = 159.38, p < 0.001), with pairwise comparisons 
showing significant differences between all electrode sites (p < 0.001; Cz>Fz>Pz), indicating 
the greatest inhibition effect at central locations. There was no significant interaction (F (2,198) 
= 0.45, p = 0.640).  
There were no differences between different symptom clusters 
There was no significant difference in the mean reaction time for correct responses between 
different three clusters (Symmetry = 348.3 ± 104.4 ms; Forbidden Thoughts = 354.4 ± 70.9 
ms; Cleaning = 362.3 ± 82.2 ms; F (3,53) = 0.536, p = 0.660). There were also no differences 
in terms of the number of omission errors (Symmetry = 2.6 ± 2.7; Forbidden Thoughts = 
2.0±2.4; Cleaning = 1.6 ± 1.7; F (3,53) = 0.507, p = 0.679) or commission errors (Symmetry = 
1.0 ± 1.0; Forbidden Thoughts = 0.5 ± 0.8; Cleaning = 1.1 ± 1.0; F (3,53) = 1.650, p = 0.189). 
 
For N2 amplitude and latency, there was no significant main effect of CLUSTER (Amplitude: 
F (2, 44) = 0.023, p = 0.977; Latency: F (2, 44) = 0.898, p = 0.415). There was also no main 
effect of CONDITION on latency (F (1, 44) = 0.092, p = 0.763). However, mirroring the whole 
cohort analysis, there was a main effect of CONDITION on amplitude (F (1, 44) = 10.241, p 
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= 0.003) with a greater response in the NoGo condition. There were no significant 
CONDITION x CLUSTER interactions (Amplitude F (2,44) = 1.78, p = 0.180; Latency F 
(2,44) = 0.31, p = 0.733). There was no significant difference between the clusters for N2d 
amplitude (F (2,44) = 0.884, p = 0.420).  
 
For P3 there was no significant main effect of CLUSTER  (Amplitude: F (2,44) = 0.23, p = 
0.799; Latency: F (2,44) = 0.27, p = 0.767), CONDITION (Amplitude: F (1, 44) = 0.04, p = 
0.849; Latency: F (1,44) = 0.13, p = 0.725) or SITE (Amplitude: F (1, 44)=8.60, p = 0.427; 
Latency: F (1.35, 59.18) = 3.42, p = 0.057). There were also no significant interactions 
(Amplitude: CONDITION x CLUSTER F (2,44) = 0.31, p = 0.736, CONDITION x SITE 
F(2,88) = 0.19, p = 0.826,  SITE x CLUSTER F (4,88) = 0.47, p = 0.760, CONDITION x SITE 
x CLUSTER F (4,88) = 1.27, p = 0.287; Latency CONDITION x CLUSTER F (2,44) = 0.54, 
p = 0.586,  CONDITION x SITE  F (1.52, 66.77) = 0.94, p = 0.374,  SITE x CLUSTER F (4, 
88) = 1.27, p = 0.287, CONDITION x SITE x CLUSTER F (3.04, 66.77) = 0.75, p = 0.526). 
P3d showed no significant main effects (CLUSTER F (2, 44) = 0.309, p = 0.736; SITE F (2, 
88) = 0.192, p = 0.826) or interaction (CLUSTER x SITE F (4, 90) = 0.97, p = 0.429). 
 
There were selected effects of comorbid depression on behavioural and ERP responses. 
The average reaction time for correct responses on the Go trials did not differ between those 
with (334.9 ± 66.8 ms) and without comorbid depression (368.6 ± 84.1; t (46) = 1.491, p = 
0.143). There were also no differences in terms of the number of commission errors made 
(OCD 1.1 ± 2.6; OCD with comorbid depression 0.6 ± 1.7; t (46) = 1.622, p = 0.101). However, 
there was a significant difference for omission errors (t (99) = 2.426, p = 0.019) with those with 
OCD (2.8 ± 0.2) making more omission errors that those with OCD and comorbid depression 
(1.3 ± 0.3).  
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For N2 amplitude and latency, there was no significant main effect of COMORBIDITY 
(Amplitude: F (1, 46) = 2.70, p = 0.107; Latency: F (1, 46) = 0.061, p = 0.806). However, as 
with the other comparisons, there was main effect of CONDITION on amplitude (F (1, 46) = 
85.98, p < 0.001) with bigger N2 responses during the NoGo condition. Again, mirroring the 
main OCD vs control analysis, there was also a significant main effect of CONDITION on 
latency (F (1, 46) = 9.46, p = 0.004), with slower responses during the Go conditions. There 
were no significant CONDITION x COMORBIDITY interactions (Amplitude F (1, 46) = 0.26, 
p = 0.613, Latency F (1, 46) = 1.78, p = 0.188). For N2d there was no significant difference 
for amplitude (F (1,46) = 2.19, p = 0.145) between those with and without comorbid 
depression.  
 
For P3 amplitude there was no significant main effect of COMORBIDITY (F (1, 46) = 0.34, p 
= 0.562). As with the main comparison between those with and without OCD, there was a 
significant main effect of CONDITION (F (1, 46) = 29.48, p < 0.001, with bigger P3 responses 
during the NoGo condition. There was a significant main effect of SITE (F (2, 92) = 76.65, p 
< 0.001) with pairwise comparisons revealing that all sites differed significantly from each 
other (p < 0.001; Cz>Pz>Fz) in the same way as the main group comparison. There was also a 
significant CONDITION x SITE interaction (F (2, 92) = 64.51, p < 0.001) following the same 
pattern as the main group analysis. There were no other significant interactions for P3 
amplitude (CONDITION x COMORBIDITY F (1, 46) = 2.72, p = 0.106, SITE x 
COMORBIDITY F (2, 92) = 0.28, p = 0.757, SITE x CONDITION x COMORBIDITY, F (2, 
92) = 1.25, p = 0291). 
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For P3 latency there was a significant main effect of COMORBIDITY (F (1, 46) = 6.02, p = 
0.018), with those with comorbid depression demonstrating faster P3 responses. There was also 
a main effect of SITE (F (2, 92) = 34.50, p < 0.001), pairwise comparisons revealed significant 
differences between Fz and Cz (p<0.001) and Fz and Pz (p < 0.001) with the fastest P3 response 
at Pz and the slowest at Fz as found for the main analysis. There was no significant main effect 
of CONDITION (F (1, 46) = 1.95, p = 0.169), but there was a significant SITE x CONDITION 
interaction (F (2, 92) = 18.20, p < 0.001) in line with the results from Hypothesis 1. There was 
a significant CONDITION x COMORBIDITY interaction (F (1, 46) = 8.80, p = 0.005); during 
the Go condition the OCD only group has a slower P3 latency compared to the OCD with 
comorbid depression, however during the NoGo condition the groups demonstrate similar 
latencies for P3. There was no SITE x COMORBIDITY interaction (F (2, 92) = 1.88, p = 
0.158). Finally, there was also a significant three-way interaction CONDITION x SITE x 
COMORBIDITY (F (2, 92) = 5.25, p = 0.007). Contrasts revealed that the group differences 
across the Go and NoGo differed across the Fz vs Pz (p = 0.004) and Cz vs Pz (p = 0.004).  
 
For amplitude of P3d there was no significant main effect of COMORBIDITY (F (1, 46) = 
2.72, p = 0.106), but there was a main effect of SITE (F (2, 92) = 64.52, p < 0.001), where 
contrasts revealed that the inhibition effect of P3d was significantly different between all 
electrode sites (p < 0.001; Cz>Fz>Pz). There was no significant SITE x COMORBIDITY 
interaction (F (2, 92) = 1.25, p = 0.291). 
Discussion 
The aim of this study was to investigate response inhibition in OCD using behavioural and 
ERP measures by examining distinct symptom clusters and the presence of comorbid 
depression. We set out to test three specific hypotheses; that there will be significant differences 
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in response inhibition between i) control and OCD participants and ii) OCD participants with 
different symptom clusters and comorbidity status. 
 
Our OCD cohort consisted of participants identified as belonging to all three of the symptom 
clusters identified and accepted as part of OCD according to DSM-5 (9, 12). Furthermore, as 
is commonly found, just over half of our participants reported comorbid depression (13). 
Together, these features suggest we had an ecological valid cohort. When this cohort was 
compared as a whole to healthy control participants, we found no differences in behavioural 
measures of response inhibition, as has been found previously (23-29). As would be expected 
for ERP components linked to response inhibition, both N2 and P3 showed greater amplitude 
in the NoGo compared to the Go condition. However, importantly for our first hypothesis, there 
were significant differences between OCD and control participants. In control participants the 
N2 component was present at both frontal and central locations, whereas within the OCD 
cohort, whilst comparable to controls frontally, N2 was absent at the central location, indicating 
a more localised response in OCD. This site-dependent effect has also been found by others 
(26, 33) and may have contributed to previous inconsistent results where different electrode 
sites had been included in analysis or combined in different ways. The OCD participants also 
had a longer latency response. Previous research has suggested that the latency of the N2 
component on this task reflects the speed of the monitoring of conflict, and therefore the 
increased latency may be indicative of OCD influencing the time course of inhibitory activity 
by slowing down the speed of response inhibition (45). The slower latency would suggest 
reduced conflict monitoring in OCD causing slower responding to the occurrence of conflicts. 
There is some evidence to support deficits in conflict monitoring in OCD (46) However the 
greater difference in N2 amplitude between the Go and NoGo condition (N2d) found in the 
present study, suggests overactive conflict monitoring in this cohort (45, 47). The conflicting 
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findings in the present study are not entirely unprecedented with a recent review suggesting 
that it is still not clear whether conflict monitoring is reliably altered in OCD (48). Based on 
the findings presented here there is evidence for slower but greater conflict monitoring. 
Interestingly, the results for P3 also show this mixed picture. We found that OCD participants 
exhibited a greater P3, implying greater response inhibition, a finding in line with previous 
research which also suggests that the increased P3 reflects hyperactivity of the underlying 
neuronal networks between the orbitofrontal and anterior cingulate cortices and basal ganglia 
in OCD (31). However, we also found a smaller P3d, indicative of reduced response inhibition 
(47).   
 
These control versus OCD participant differences, whilst interesting, are not new findings. The 
critical element of the current study was to investigate whether there were differences between 
clusters or those with and without comorbid depression, which may have confounded previous 
studies. The cluster analysis revealed no differences between the clusters on any measure of 
response inhibition. This indicates that cohorts with different symptom clusters have not 
contributed to the inconsistent results previously found. However, it is important to 
acknowledge that whilst the overall sample size for the OCD cohort in the present study is 
considerably larger than has been found in many previous studies (22, 24, 26, 33, 46, 49), the 
number of participants in each cluster was limited, especially for the Symmetry cluster.  
 
The comparison of OCD participants with and without comorbid depression revealed that those 
with OCD only made more errors of omission that those with comorbid depression. This was 
the only significant difference found in any behavioural measure for this study. Errors of 
omission can be considered an index of response execution, as opposed to errors of 
commission, which are an index of response inhibition. The increased level of omission errors 
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in those with OCD only is indicative of a deficit in sustained attention (50). Whilst the higher 
level of omission errors reported here contrasts with previous work where OCD (in the absence 
of comorbidities) was associated with a decrease in omission and an increase in commission 
errors (22), it is in line with studies showing poorer sustained attention in OCD (51, 52). 
However, this does not explain why the presence of comorbid depression would effectively 
protect again errors of omission. Previous research has shown errors of omission in depressed 
participants are comparable to control participants (53) but there is no evidence to suggest those 
with comorbid depression somehow have improved sustained attention, although this may be 
something to consider in future research. Irrespective of this, the present data suggest that this 
particular deficit in OCD leading to increased errors of omission is not due to the presence of 
depression as has been previous suggested (54) and more recently discounted elsewhere (55, 
56).  
 
There were no significant group differences for most ERP measures but there was a reduced 
latency for P3 in those with comorbid depression. This is  in line with previous studies of 
depression showing a short latency P3 in patients with depression relative to healthy controls 
(57). P3 latency is believed to represent the speed of high-level cognitive activity (58) such that 
a decrease in latency would suggest an increase in the speed of processing during the stimulus-
evaluation and decision-making phases of response. These results, as with the findings on 
errors, imply that the presence of comorbid depression somehow supports improved task 
performance. It remains to be seen whether this arises because of effective compensation 
mechanisms or prior treatment of depression (because current treatment was matched in the 
present study), for example. Whilst the impact on response inhibition reported here is small, 
the prevalence of this comorbidity is high and, therefore, it can be argued that it is beneficial 
to differentiate comorbidity in analyses of response inhibition. Given these findings, it is 
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possible that the presence of comorbid depression could have had a small impact on previous 
results in response inhibition studies with OCD participants. However, it is important to 
recognise the limitations of the work presented here. Whilst the sample size for the two groups 
was satisfactory, we did not independently assess depression.  
 
As well as the limitations of sample size discussed above, it is important to note that this study 
used only one measure of response inhibition – the Go/No-Go task – and this is a limitation. 
Response inhibition is not a unitary trait, it involves three distinct elements: action 
postponement, action restraint and action cancellation (59) and different tasks access different 
sub-components of response inhibition. The Go/No-Go task may contain response-selection 
and ‘waiting’ elements but does not access information related to response cancellation (60). 
One task that does access this is the stop-signal task (SST), but this in turn does not access the 
sub-components available from the Go/No-Go task (60). Perhaps unsurprisingly given that they 
access different subcomponents of response inhibition, performance on these tasks relies on 
slightly different neural circuitry with the Go/No-Go task highly dependent on the inferior 
frontal cortex and the SST more reliant on normal functioning of the dorso-medial striatum 
(61-63). Previous studies with OCD participants have revealed that there are changes in the 
inferior frontal cortex for regional blood flow (64, 65), grey matter volume (66) and activation 
during Go/No-Go tasks (67). However, OCD is also linked to changes in cortico-striatal 
circuitry, albeit with most changes noted for the ventral rather than dorsal striatum (68). 
Nonetheless this means that using the SST may be a worthwhile future investigation for this 
clinical group. In addition to only using one task, we only included participants with comorbid 
depression because this has been shown to be the most comorbidity found in over 50% of 
individuals with OCD (13). However, there are several other comorbid conditions which are 
relatively common in OCD including social phobia (35.3%), generalised anxiety disorder 
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(34.1%) and specific phobia (31.6%). Therefore, these additional comorbidities may also 
impact on the measures we collected and future studies should consider including a wider range 
of comorbidities.  
Conclusions 
In summary, the current study has examined response inhibition in different clinical subgroups 
within OCD, an important step in revisiting research where the heterogeneity of the condition 
has been overlooked previously. From the results, we can conclude that symptom cluster is 
unlikely to have contributed to the previous inconsistencies in findings. However, the presence 
of comorbid depression may have a small impact on results and, therefore, should be 
considered for separate analysis in future studies. 
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Figures 
Figure 1 Timescale of the stimulus presentation of the Visual Continuous Performance Task 
(VCPT) (A) The stimuli presented for each of the key conditions (B).  
Figure 2 There were no differences in the reaction times for correct responses (A), omission 
(B) or commission errors (C) between the control and OCD group. Due to the low error number, 
data is shown as mean ± SEM. 
Figure 3 Normalised grand averages of OCD (grey) and control groups (black) during Go and 
NoGo conditions and the NoGo-Go difference waveforms. Dotted lines indicate stimulus 
onset. The vertical scale bar is 4µV and the horizontal scale bar is 400ms. 
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Tables  
Table 1 Summary of participant characteristics matched between OCD (N = 48) and control (N 
= 53) participants. All continuous variables are given as mean ± SD.  Matching was confirmed 
with independent sample t-tests (age and years in education) or chi-square test of independence 
(gender and handedness). 
 OCD Control Test 
statistic 
Df p-value 
Male 18 18 0.14 1 0.711 
Female 30 35 
Handedness Right 26 29 0.27 2 0.873 
Handedness Left 17 20 
Handedness 
Ambidextrous 
5 4 
 Mean SD Mean SD    
Age (years) 36.1 11.4 40.3 11.6 1.89 99 0.062 
Years in 
Education 
14.8 2.6 15.6 2.7 1.45 99 0.150 
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Table 2 Summary of participant characteristics matched between distinct OCD symptom 
clusters (Symmetry N=7; Forbidden Thoughts N=25, Cleaning N=16). All continuous variables 
are given as mean ± SD. Matching was confirmed with One-Way ANOVA or Chi-square test  
 Symmetry 
 
Forbidden 
Thoughts 
Cleaning Test 
statistic 
Df p-
value 
Male 2 11 5 0.96 2 0.620 
Female 5 14 11 
Handedness: 
Right 
4 14 8 5.81 4 0.214 
Handedness: 
Left 
3 10 4 
Handedness: 
ambidextrous 
0 1 4 
Medication: 
none  
2 12 4 8.85 4 0.065 
Medication: 
antidepressant 
2 11 10 
Medication: 
Other 
3 2 1 
No CBT 4 18 14 2.64 2 0.267 
CBT 3 7 2 
OCD only 3 9 8 0.79 2 0.673 
Comorbid 
Depression 
4 16 8 
 M SD M SD M SD    
Age (years) 37.6  9.4 34.1 11.2 38.4 12.5 0.77 2 0.471 
Years in 
Education 
13.9 3.8 15.3 2.2 15.5 2.5 1.00 2 0.376 
Age of onset 
(years) 
32.3  3.6 26.1 1.91 25.7 8.2 1.48 2 0.239 
Illness 
duration 
(months) 
63.0  65.6 96.7 103.5 153.1 133.4 2.03 2 0.144 
Illness Severity  26.4  5.1 23.2 5.4 26.1 5.6 1.89 2 0.163 
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Table 3 Summary of participant characteristics matched between those with OCD only (N = 
20) and those with OCD and depression diagnoses (N = 28). All continuous variables are given 
as mean ± SD. Matching was confirmed with independent sample t-tests (continuous variables) 
or chi-square test of independence (categorical). 
 OCD only OCD + depression Test 
statistic 
Df p-value 
Male 10 8 1.04 1 0.306 
Female 10 20 
Handedness: 
Right 
8 18 3.34 2 0.189 
Handedness: 
Left 
10 7 
Handedness: 
ambidextrous 
2 3 
Medication: 
none  
10 8 3.42 2 0.181 
Medication: 
antidepressant 
8 15 
Medication: 
Other 
1 5 
No CBT 16 20 0.46 1 0.499 
CBT 4 8    
 M SD M SD    
Age (years) 34.0 11.8 37.5 11.0 0.14 46 0.886 
Years in 
Education 
14.8 3.1 14.9 2.2 1.00 46 0.376 
Age of onset 
(years) 
26.0 1.9 27.5 9.9 0.54 46 0.592 
Illness 
duration 
(months) 
96.7 115.4 120.5 112.2 0.72 46 0.478 
Illness Severity  24.3  5.7 24.9 5.5 0.34  46 0.736 
 
 
